C
lass II MHC molecules are heterodimeric (ot/~) transmembrane glycoproteins. They are expressed at the surface of antigen-presenting cells (macrophages, dendritic cells, B cells), where they present bound peptides for surveillance by CD4 + T cells. Peptides that become bound to class II molecules are generated by processing events within the endocytic pathway, and the predominant class II-associated peptides derive from membrane and extracellular proteins (1, 2) . Detection of peptide/dass II molecule complexes with specific T cells suggests that some peptides derived from other sources also become associated with class II molecules (3, 4) .
The formation of intracellular complexes between MHC class II molecules and peptides is a regulated process. One molecule involved is the invariant chain (Ii), which associates with nascent class II molecules and mediates their localization to endocytic compartments through a sequence in its cytoplasmic tail (5, 6) . Ii cleavage and dissociation are apparent prerequisites for class II molecule/peptide binding (7) . Expression of the p41 form of Ii, which has an alternatively spliced intraluminal portion, increases efficiency of presentation of certain antigens, perhaps by further modulation of dass II molecule trafficking (8) . A second regulatory molecule is implied by data from mutant B lymphoblastoid (B-LCL) 1 cell lines that are defective in dass II-restricted antigen presentation, but express normal levels of both invariant chain and class II molecules (9) . The defect in these 1 Abbreviations used in this paper: B-LCL, B-lymphoblastoid; C2P-1, class mutants affects generation of peptide/class II molecule complexes from endocytosed proteins, resulting in deficient presentation of intact protein antigens (though not of synthetic peptides) and in altered conformation of class II molecules expressed at the cell surface. The gene responsible for this phenotype (hereafter called "class II presentation locus" [C2P-1]) maps to the MHC (10) (11) (12) , but its identity and specific function are unknown.
Analyses of the relationship of fine structure to function in MHC class II molecules have delineated regions or residues involved in T cell receptor recognition (summarized in reference 13), peptide binding (13, 14) , interaction with the CD4 molecule (15, 16) , and most recently, dass II dimer-dimer interactions (14) . However, regions of MHC class II molecules specifically related to peptide loading have not been mapped. To elucidate structure-function relationships in human class II molecules, we have isolated informative mutant B-LCLs (17, 18) . Here, we describe a novel B-LCL, 10.24.6, in which HLA-DR molecules with an a2 domain mutation fail to become appropriately loaded with naturally processed peptides, even though the mutant molecules are capable of binding DR-restricted peptides in vitro and the class II molecule loading pathway is intact in the cells. Our findings indicate that normal intracellular formation of peptide/HLA-DR complexes involves the region of the DR molecule altered by the 10.24.6 mutation. Further, as the phenotype of the mutant DR molecules resembles that of DR molecules in a C2P-1 mutant derived from the same progenitor, our findings suggest that class II molecules and the C2P-1 regulatory protein may directly interact.
Materials and Methods
Antigen-presenting Cell Lines. The progenitor cell line, 8.1.6, is a DR/DQ hemizygous B-LCL that expresses the HLA class II specificities DR3, DRw52a, DQ2, and DP4.1, DP4.1 (reference 17). To derive mutant 10.24.6, a young clone of 8.1.6 was mutagenized with ethyl methane sulfonate and immunoselected with mAb 16.23 plus complement, as described (see reference 17 for details). Mutants 9.5.3, 9.10.3, and 10.53.6 are C2P-l-defective mutants (see text), which were also derived from progenitor 8.1.6 by immunoselection with mAb 16.23; the phenotypic characteristics of these mutants have been previously described in detail (9). 9.22.3 is a DR-null B-LCL, derived from 8.1.6 by ddetion of the single DRA gene in 8.1.6 (reference 17); 9.22.3 retains expression of HLA-DQ and -DP molecules and presents DQ-and DP-restricted antigens normally (19) . To generate the 10.24.6 x 9.22.3 hybrid, dominant sdectable markers were introduced into 9.22.3 and 10.24.6. An Escherichia coli gpt gene, conferring resistance to mycophenolic acid, was transferred into 9.22.3 by electroporation as described (20) . The dihydrofolate reductase gene, conferring resistance to methotrexate, was introduced into 10.24.6 by coculture with PA317-SDHT, a retrovirus packaging fibroblast line, provided by A. Dusty Miller, Fred Hutchinson Cancer Research Center, Seattle, WA. Somatic cell hybrids were prepared by polyethylene glycol (PEG) fusion, as described (9) . For generation of the 10.24.6-DRA transfectant, 10.24.6 was cocultured with PA317LHC-DILAc6, a retrovirus packaging fibroblast line containing the DILA cDNA and the hygromycin phosphoribosyl transferase gene (21) 
T Cells and T Cell Proliferation
Assays. The DR3-restricted T cell clone specific for residues 241-265 of the major outer membrane protein (MOMP) of Chlamydia trachomatis was isolated as described (Barbosa, J., manuscript submitted for publication) and kindly provided by Dr. James Barbosa, Miles, Inc., West Haven, CT. The other antigen-specific T cell clones and lines were isolated and characterized as described (9, 19) . The alloreactive, anti-DR3 clone was isolated as described (22) and was the gift of Dr. Armead Johnson, Georgetown University, Washington, DC. The alloreactire, anti-DQ2 done (Cotner, T., unpublished results) was the gift of Dr. Tom Corner, University of Washington, Seattle, WA. The alloreactive, anti-DP4 T cells were isolated as described (23) .231 reacts with HLA-DR and -DP dimers and -DR and -DP fl chain monomers. Primary references for these antibodies are cited in reference 9, with the exceptions of NDS-9 (reference 25), L243 (reference 26), and DA6.231 (reference 27). Cell surface radioimmune binding was performed as described (17) . Immunofluorescence analysis was carried out using saturating amounts of unlabeled primary antibody, followed by fluoresceinated goat anti-mouse IgG (H+L) (Tago Inc., Burlingame, CA). Staining with secondary antibody alone was used as a control for background fluorescence. Samples were analyzed on an EPlCS-C (Coulter Electronics, Inc., Hileah, Florida).
Sequence AnalTsis. Sequence analyses of the DRA and DRB genes of 8.1.6 and 10.24.6 were carried out as described (18) . Briefly, cDNAs prepared from poly(A) + RNA from 8.1.6 and 10.24.6 were subjected to PCR amplification using DRA and DILB primer pairs (see reference 18 for primer sequences). Size-selected doublestranded PCR DNA was subjected to dideoxy sequencing using Western Blot Analysis and Dimer Stability Ability. This assay has been described (17) . Briefly, unboiled, whole-cell NP-40 extracts were analyzed by one-dimensional SDS-PAGE and immunoblotted with various antibodies: anti-DR mAb DA6.147, anti-DP mAb B7/21.2, or anti-DR/DP mAb DA6.231. For endoglycosidase F experiments, whole cell lysates were acetone precipitated, dissolved in 100 mM Tris-HC1, pH 8.0, 0.5% SDS, 10% 2-ME, 10 mM EDrA, and boiled for 3 min. NP-40 was added to a concentration of 1%, and samples were incubated for 1.5 h at 37~ with or without 1.5/~1 of 50 U/m1 endoglycosidase F (Boehringer Mannheim Corp., Indianapolis, IN). Samples were analyzed on a 10% SDS-PAGE gel and immunoblotted with mAb DA6.147, which recognizes DRop.
Reconstitution of HLA-DR Dimer Stability in SDS Using Added
Pept/d~ Dimer reconstitution was carried out using published methods (29, 30) , with modifications. Briefly, 107 cells from progenitor 8.1.6 and mutant 10.24.6 were hbeled for 6 h at 37~ with 1.0 mCi [3SS]methionine and chased for 18 h. HLA-DR3 molecules were arfinlty purified using the I-ILA-DR-specific mAb L243 (reference 26). For incubation with peptide, aliquots of affinitypurified material were acidified from pH 8.0 to 4.5 with 1.7/~1 1 M acetic add, incubated for 3 h at 37~ with DR3-binding peptides (MOMP 251-265 or heat-shock protein 65 3-13), and neutralized with 1.4/~1 1 M Tris. Peptides were present at a final concentration of 100/~M. Boiled samples were heated to 100~ for 5 min. All samples were analyzed by nonreducing SDS-PAGE dectrophoresis.
Ion Exchange-HPLC and Sequence Analysis of HLA-DR-associated
Apt/des. 109 cells from the progenitor line 8.1.6 and mutants 10.24.6 and 9.5.3 were lysed for 60 min at 4~ in 0.01 M Tris, 0.15 M NaC1, pH 7.4, containing the detergent polyoxyethylene-9-1aury! ether and proteinase inhibitors (0.1 mM N-tosyl-Llysine chloromethyl ketone, 0.5 mM phenylmethylsulphonyl fluoride, 0.5 mM iodoacetamide and 10 #g/ml aprotinin). HLA-DR3 molecules were purified from chrified cell lysates by immunoaffinity chromatography using the HLA-DR-specific mAb L243 (reference 26) and concentrated on a Centripep-30 (Amicon, Beverly, MA). Protein yields were estimated by gel filtration. The affinity-purified HLA-DR3 (400/~g) was ethanol-precipitated, dissolved in 0.1% trifluoroacetic acid in 20% acetonitrile, and incubated at 37~ for 2.5 h. Peptides were separated by ion exchange chromatography on a Mono-S HR5/5 column (Waters Associates, Milford, MA).
The following ehtion buffers were used: buffer A (0.1% TFA in 20% acetonitrile); buffer B (1 M NaC1 in buffer A). The column was equilibrated in buffer A and the peptides were eluted with a gradient of 0-100% buffer B from 5-60 min at a flow rate of 0.5 ml/min. Injection volume was 200/~1. Peptides were detected by monitoring the absorbance at 214 nm. The material in the major peaks was further purified on an Aquapore RP300 reverse phase column (100 x 2.1 mm) using a 1040A HPLC system with a gradient of 10-40% acetonitrile in 0.1% TFA in water from 0-30 min at a flow rate of 0.1 ml/min (both from Applied Biosystems Inc., Foster City, CA (Fig. 1, A  and B ). In addition, the mutation introduces an N-linked glycosylation sequence (Asn-X-Ser), which directs carboby&ate addition at residue 94N (Fig. 1, A and B) . DKcx chains in 10.24.6 are indeed modified by an extra N-linked carbohydrate moiety; they are ~3 kD higher in apparent molecular mass than DRcx chains of progenitor 8.1.6 (Fig. 2, A and B) and this molecular weight disparity is abolished when DRc~ chains of 10.24.6 and 8.1.6 are treated with endoglycosidase F, which removes N-linked sugars (Fig. 2 A) . N-linked carbohydrate) . Untreated and endo F-treated samples were analyzed by one-dimensioml SDS-PAGE and hnmunoblotted with mAb DA6.147, which reacts with DRc~ monomers. (/3) HLA-DR, but not -DP dimen extracted from mutant 10.24.6 dissociate into monomefic subunits/n one-dimensional SDS-PAGE. Westea'n blot analysis of detergent (N~0) ~tracts of indicated cell lines:
10.24.6, DRA point mutant; mutants 9.5.3, 9.10.3, and 10.53.6, 8.1.6-derived C2P-1 presentation mutants (reference 9 and E. Mdlins, unpublished data); 9.22.3, 8.1.6-derived DR-null mutant, which ~presses HLA-DQ and FILA-DP molecules (17); 8.1.6, progenitor line. Unboiled, whole-cell ~tracts were analyzed by oneMimemional SDS-PAGE and immunoblotted with anti-DR mAb DA6.147 (kfi); or with anti-DP mAb B7/21.2 (m/ddk); or with anti-DR and -DP mAb DA6.231 (right). Because B7/21.2 reacts only weakly with monomers, the altered stability of the DP molr in mutant 9.5.3 is best evaluated by the disappearance of DP dime, (lane 4, m/rid/e). DR-null mutant 9.22.3 is indoded as a control for antibody spcciticity; as expected, the dim~ band from 9.22.3 is equivalent in intensity to that of 8.1.6 with the anti-DP antibody (m/rid/e) but of lower intensity than that of 8.1.6 with antibody that recognizes both DR. and DP molecules (right). FILA-DP dimen of 10.24.6 appear unaffected by the 10.24.6 DRA mutation, as ~tpected, since DR~x/DP8 dimers are ~pressed infrequently, if at all, in these cells (E. Mellins, unpublished results). minant is apparently also affected by the 10.24.6 mutation. Of interest, the pattern of binding of anti-DR3 antibodies to mutant 10.24.6 resembles that observed with the 8.1.6-derived C2P-1 mutants, which have wild type DRA and B gene sequences, but are deficient in intracellular formation of peptide/class II molecule complexes (e.g., mutant 9.5.3, Table 1 ). These results suggest that the DR molecules of 10.24.6 and those of C2P-1 mutants have similar changes in conformation at their peptide binding domains.
The Mutant HLA-DR Dimers Are Unstable in SDS Detergent. To further assess the structure of class II molecules in mutant 10.24.6, we utilized an assay of class II dimer stability. Stability in SDS detergent solutions is a characteristic of a proportion of the mature class II molecules that have bound peptide (29, (35) (36) (37) ; class II dimers of C2P-1 mutants, on the other hand, are unstable in SDS (9) . As shown in Fig. 2 B, the vast majority of HLA-DR dimers extracted from mutant 10.24.6 resemble those from C2P-1 mutants (e.g., 9.5.3, 9.10.3, 10.53.6) and dissociate into monomers in SDS-PAGE. However, the HLA-DP dimers of 10.24.6 and progenitor 8.1.6 maintain stability in SDS, unlike HLA-DP dimers in C2P-1 mutants (Fig. 2 B, middle and right) . The SDS instability of the mutant DR molecules in 10.24.6 indicates that these molecules are altered in conformation compared to the majority of the HLA-DR molecules in the progenitor cell; the fact that SDS instability is limited to HLA-DR molecules in 10.24.6 implies that this phenotype results from mutation of the DRA gene.
We considered several mechanisms that might be the basis of the SDS unstable phenotype of HLA-DR dimers in mutant 10.24.6. SDS instability is observed in nascent class II molecules before dissociation of Ii chain (36) , and in class II molecules (e.g., I-A k) synthesized in the absence of invariant chain (38) . However, neither lack of nor prolonged association with intact invariant chains explains the SDS instability of the HLA-DR molecules of 10.24.6, as the kinetics of Ii association and dissociation from the mutant DR molecules are normal (Amaya, M., and E. Mellins, data not shown). SDS instability is also a feature of class II molecules that lack immunogenic peptides, such as insect cell-derived HI.A-DR1 molecules devoid of peptides (39) , and class II molecules of C2P-1 mutants, which are defective in generating peptide/MHC class II complexes. To determine whether altered peptide loading is the basis of SDS instability in the HLA-DR molecules of 10.24.6, we first used antigen presentation to class II-restricted T ceils to assess formation of class II/peptide complexes from endocytosed proteins. Fig. 3 a shows a comparison of T cell stimulation by 10.24.6 and progenitor 8.1.6. When provided with intact protein as antigen, the 10.24.6 mutant is unable to stimulate DR3-restricted T ceils. An allospecific anti-DR3 T ceil done whose reactivity is apparently peptide dependent (24) is also nonresponsive to 10.24.6 cells. In contrast, T cells restricted by the appropriate HLA-DQ and -DP alleles readily respond to 10.24.6 cells as antigen presenting cells. These results indicate that generation of peptide/HLA-DR complexes is impaired in 10.24.6. The DRospecific defect in mutant 10.24.6 cells reflects exclusion of the mutant DR molecules from participation 545 Mellins et al.
in the peptide-loading pathway, rather than the absence of a DR-specific accessory factor, since the 10.24.6-DRA transfectant regains the ability to stimulate DR3-restricted T ceils (Hg. 3 a), whereas a somatic cell hybrid between 10.24.6 and a homozygous DRA deletion mutant (10.24.6 x 9.22.3) maintains the mutant phenotype (Fig. 3 a) .
Mutant HLA-DR Molecules in I0.24.6 Bind DR-restricted tides. It was possible that the mutant DR molecules in 10.24.6 were unable to participate in the normal process of peptide loading because their altered structure rendered them unable to bind peptides. To evaluate this possibility, we first tested the ability of 10.24.6 cells to stimulate DR-restricted T ceils with peptide antigen. As shown in Fig. 3 b, HLA-DR molecules expressed by 10.24.6 present two DR-restricted peptides, one from the MOMP of C. trachomatis (241-265) (Barbosa, J., manuscript submitted for publication) and one from TT (1274-1285) (reference 40). These results indicate binding of immunogenic peptides to DR molecules of 10.24.6, however, they leave open the possibility that only a small fraction of 10.24.6 DR molecules, sufficient for T ceU stimulation (41) , is capable of binding peptide. We therefore utilized an assay in which peptide binding to the mutant molecules was detected by reconstitution of SDS-stable dimers (29, 30) . In the absence of added peptide, DR3 molecules affinity purified from mutant 10.24.6 dissociate into monomers in SDS without boiling, whereas DR3 molecules affinity purified from progenitor 8.1.6 maintain the dimeric state in SDS, unless boiled (Fig. 4) . After incubation at pH 4.5 with either of two DR3-restricted peptides (MOMP [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [265] or mycobacterial heat-shock protein 65 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [reference 42]), a majority of the affinity purified DR molecules from 10.24.6 forms SDS stable dimers, implying they have bound peptide (Fig. 4) . These results, together with the peptide presentation assays, indicate that the structural changes and functional defects in the DR molecules of 10.24.6 are unlikely to derive from an intrinsic inability of the mutant molecules to bind immunogenic peptides.
HLA-DR Molecules in Mutant 10.24.6 and in C2P-1 Mutant 9.5.3 Are Associated with Invariant Chain Peptides. The SDS instability of HLA-DR3 molecules in mutant 10.24.6 thus appears to reflect a defect in the loading of these molecules with naturally processed peptides. To directly evaluate peptide occupancy of DR molecules in 10.24.6, we affinity purified HLA-DRcffB dimers, extracted the associated peptides, and analyzed the peptides by ion exchange and reverse phase HPLC. Further, as the antibody binding profile, dimer instability, and antigen presentation defects of the HLA-DR3 molecules of 10.24.6 mimicked those of the DR3 molecules of C2P-1 presentation mutants, we compared the profiles of peptides eluted from the DR3 molecules of 10.24.6 to those eluted from 9.5.3, a representative C2P-1 mutant. Fig. 5 a shows the chromatograms of HLA-DR3-assodated peptides from mutants 10.24.6, 9.5.3, and progenitor 8.1.6. Based on integration of the A2t4 trace of these chromatograms, mutant and progenitor-derived DR3 yielded similar amounts of total peptides per mole of protein (70-85% of the starting amount). However, the profiles of peptides extracted from HLA-DR3 molecules of the two mutants contain a set of prominent peaks HLA-DK molecules were ai~nity purified from metabolicallylabeled (6-h pulse/18-h chase) progenitor 8.1.6 and mutant 10.24.6 cells. DR molecules were treated as indicated (see Materials and Methods for details) and analyzed by SDS-PAGE. The bands in the dimer region of the boiled 8.1.6 sample and the non-boiled and boiled 10.24.6 samples likely reflect the "floppy" dimer conformation, which runs at a higher apparent molecular weight in SDS-PAGE (29) .
that are present at most in trace amounts in the eluate of the progenitor cells. We identified the peptides corresponding to these peaks by a combination of NHz-terminal Edman degradation and mass spectrometry after further purification by reverse phase HPLC. As shown in Fig. 5 b, the DK3-associated peptides from the mutants derive from a common region of the invariant chain (residues 80-103). Using A214 absorbance, we estimated that at least 60% of the total isolated peptides from both 10.24.6 and 9.5.3 was derived from Ii. None of the same peptides was detectable by reverse phase chromatography or mass spectrometry in the ehate from 8.1.6 cells (Cameron, P., unpublished results). The observation that HLA-DK3 molecules from mutants 10.24.6 and 9.5.3 are associated with the same Ii-derived peptides reveals the struc- rural basis for their similar phenotypes and confirms that in both mutants HLA-DR molecules fail to mature to appropriately loaded species.
Discussion
In mutant 10.24.6, striking alterations in the structure and antigen presentation function of the HLA-DR molecule are associated with a point mutation in the DRA gene. The phenotype of the mutant molecules can be specifically attributed to the DRA mutation, as transfection of 10.24.6 cells with a wild type DRA gene restores the wild type phenotype (Table 1 and Fig. 3 ). The mutation results in two structural changes in the DRot chain: (a) loss of a proline residue, 96P, which is highly conserved in murine and human class II o~ chains (43) and likely interacts with a conserved ~ chain residue ( Fig. 1 a) ; and (b) addition of a bulky carbohydrate adduct to the o~2 domain. The latter effect of the mutation may be more critical for the phenotype of the molecules because the particular amino acid substitution in DRoL, serine for proline, is a relatively conservative change (44) .
The key features of the DR molecules expressed by the 10.24.6 mutant, loss of expression of certain antibody epi- 547 Mellins et al.
topes, altered stability in SDS detergent solution, and deficient DR-restricted presentation of endocytosed protein, but not peptide, suggest a defect in formation of complexes between DR molecules and naturally processed peptides. In this report, we demonstrate that the mutant molecules are predominantly associated with peptides derived from Ii (residues 80-103), and are in this regard similar to DR molecules of antigen presentation mutants with defects in an MHC-linked gene(s) (Fig. 5, and references 30, 45 ). Fragments derived from the same region of invariant chain have also been found in association with several class II alleles in both human and murine wild type cells (1, 2, 46) . The Ii-derived peptides may represent products of Ii proteolysis that reassociate with class II molecules (in competition with available immunogenic peptides) or they may be residual fragments of Ii that require removal to allow binding of immunogenic peptides. The DR eluates from both mutant 10.24.6 and the C2P-1 mutant 9.5.3 also contain non-Ii peptides, but these have not yet been characterized. Analysis of these non-Ii peptides may also shed light on the nature of the defect(s) in the two mutant cells. Mutant 10.24.6 is unique in having a defined genetic lesion in DRA that yields HLA-DR molecules predominantly associated with Ii-derived peptides. Several mechanisms may be envisioned to account for this phenotype in 10.24.6 cells. (a) The mutant DR molecules have increased affinity for Iiderived peptides. While this alternative can not be ex_cluded, carbohydrate addition to DRo~ is more likely to introduce steric inhibition of a critical interaction than to enhance affinity for an associated peptide. (b) The DRA mutation alters trafficking of DR molecules such that they do not encounter immunogenic peptides. The mutant molecules are known to arrive at a peripheral endocytic compartment where Ii proteolysis is accomplished; however, peptide loading may require transport to another compartment. This transport may be mediated by a non-Ii chaperone, which does not recognize the mutant DR molecules. Alternatively, transport of DR molecules may require homotypic aggregation, which is blocked in the mutant molecules. Homotypic interaction between HLA-DR1 molecules occurs during crystallization (reference 14) , and the resulting dimer of dimers includes an interface near the region of DRol altered by aberrant glycosylation in 10.24.6. (c) The DR molecules in 10.24.6 reach the appropriate subcdlular location but are unable to participate in the peptide-loading process. The mutant molecules are capable of binding and presenting extracellular peptides. However, physiologic formation HLA-DR/peptide complexes may involve an accessory molecule that either removes Ii fragments or loads immunogenic peptides. The altered DRot chain in 10.24.6 could hinder the binding or activity of such a molecule.
In several of the mechanisms proposed to account for the 10.24.6 phenotype, interaction between the HLA-DR molecule and a non-Ii accessory molecule is postulated. Antigen presentation mutants with defects in the MHC-linked C2P-1 gene provide evidence for such a non-Ii accessory molecule and indicate its critical function in the generation of peptide/class II molecule complexes. Indeed, as mutation of the C2P-1 gene and the DRA gene both generate HLA-DR tool-
